Authors
Sidhant Seth, Matthew R Wilson
Published in
Current opinion in oncology. Nov 17, 2026. Epub Nov 17, 2026.
Abstract
Primary testicular diffuse large B-cell lymphoma (PT-DLBCL) is a rare but clinically important lymphoma subtype characterized by a distinct pattern of relapse, particularly involving the central nervous system (CNS) and contralateral testis. This review summarizes recent advances in the biology and management of PT-DLBCL, with a focus on developments from the past 18 months.
Recent genomic, transcriptomic and immune profiling studies have demonstrated marked biological heterogeneity within PT-DLBCL, extending beyond its predominant MCD/C5 molecular background. Distinct genomic subtypes, transcriptional programmes and immune microenvironmental features have been identified, including mechanisms of immune escape mediated by impaired antigen presentation. Clinically, CNS relapse remains a major challenge. Although CNS prophylaxis, including high-dose methotrexate, has been incorporated into standard practice, recent retrospective analyses have questioned its ability to significantly reduce CNS relapse risk.
PT-DLBCL is evolving from a disease defined primarily by anatomical site towards one increasingly informed by molecular and immune biology. These advances provide a rationale for future biology-driven approaches, including therapies targeting B-cell receptor signalling and immune-based strategies. However, prospective collaborative studies incorporating genomic profiling, immune characterization and molecular monitoring will be required to translate these insights into improved patient outcomes.
PMID:
43038222
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0